Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $235.71

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month price target among […]

Related Keywords

,Stifel Nicolaus ,Raymond James ,Yvonne Greenstreet ,Pushkal Garg ,Alnylam Pharmaceuticals Company Profile ,Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Inc ,Needham Company ,News Ratings For Alnylam Pharmaceuticals Daily ,Alnylam Pharmaceuticals Price Performance ,Analyst Recommendations For Alnylam Pharmaceuticals ,Osaic Holdings Inc ,Securities Exchange Commission ,Nasdaq ,Institutional Trading Of Alnylam Pharmaceuticals ,S Capital Wealth Advisors ,Barclays Plc ,Citigroup ,National Pension Service ,Get Free Report ,Exchange Commission ,Wealth Advisors ,Pension Service ,Get Free ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Ratings ,Consensus ,